Fangda Partners maintains a strong position in the life sciences and healthcare market, providing a comprehensive offering that spans asset transactions, licensing, and M&A-related work. The practice is led from the Shanghai office by seasoned trio Josh Shin, Diana Li and Michael Han. Shin has a particular specialism in corporate and commercial law and is sought out by pharma and life sciences sector clients, while Li focuses on M&A, private equity and foreign direct investments dedicated to the pharmaceutical, healthcare and bioscience industries. Han is well-versed in joint ventures, horizontal and vertical arrangements and antitrust litigation. Other key lawyers include Henry He, who excels in complex cross-border transactions involving IP, strategic partnerships and clinical trial operational matters. Bella Wang is noted for her expertise in corporate and commercial transactions.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- ''The team navigates complex regulatory frameworks and commercial transactions in this industry, which requires both sector-specific knowledge and an ability to recognise emerging issues, and the firm excels on both counts.'
- 'Josh Shin is greatly valued for the practical and commercially focused solutions he delivers; his understanding of the nuances and challenges unique to pharma and biotech projects has positioned him as a trusted advisor to our business.'
- 'Josh Shin greatly values the practical and commercially focused solutions delivered; his understanding of the nuances and challenges unique to pharma and biotech projects has positioned him as a trusted advisor to our business.'
- 'The impressive depth of experience in the life sciences sector has been consistently apparent in the sophisticated advice Fangda provides.'
- 'Navigating complex regulatory frameworks and commercial transactions in this industry requires both sector-specific knowledge and an ability to recognise emerging issues, and the firm excels on both counts.'
- 'The team is familiar with relevant industry practices, transaction models, and law enforcement trends in the biopharmaceutical industry.'
Key clients
- AstraZeneca
- Abbvie
- BMS
- Biogen
- Biotrack Capital
- Bao Pharma
- BioSion
- C-Stone
- China Medical System
- Chinese University of Hong Kong
- CSPC Pharmaceuticals
- Chongqing Huishang Medical Technology Co., Ltd.
Work highlights
Assisting MSD to enter an exclusive global license to develop, manufacture and commercialise LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.
Assisting XtalPi with an IPO that marked a strategic milestone for the AI-driven drug and materials discovery firm, enabling it to attract global investors and enhance liquidity for shareholders.
Represented DualityBio in reaching a collaboration with 3S Bio on the commercialisation of one of Duality Bio’s major drug products, assisting with the due diligence, contract drafting, review, modification and negotiation of the license agreement.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Bella Wang
Practice head
Josh Shin; Diana Li; Henry He
Other key lawyers
Henry He; Bella Wang